NICE recommends Wegovy only within specialist weight management services with specific eligibility criteria
What are the adverse reactions
They included 12 SGLT2i trials with 73,238 participants, of whom 3,065 were on a GLP-1 RA: they found that the benefits of SGLT2i on MACE were consistent regardless of background GLP-1 RA use (HR = 0.81 in patients receiving GLP-1 RA vs HR = 0.90 in those not receiving GLP-1RA) with no significant heterogeneity (p = 0.31)
Consider the types of foods you eat
Genetic diseases with pigmentary manifestations (eg, oculocutaneous albinism, piebaldism, Waardenburg syndrome, tuberous sclerosis, neurofibromatosis) are reviewed in Chapter 360
Some formulations may contain sugars or other excipients that could theoretically contribute to caloric intake, though the amounts are typically negligible